Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcome.

OncoImmunology

1 février 2013
Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+NK cell levels correlate with disease outcome.

Chaput N, Flament C, Locher C, Desbois M, Rey A, Rusakiewicz S, Poirier-Colame V, Pautier P, Le Cesne A, Soria JC, Paci A, Rosenzwajg M, Klatzmann D, Eggermont A, Robert C,Zitvogel L.